These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21987240)

  • 21. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.
    Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O
    J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
    Wacke R; Förster S; Adam U; Mundkowski RG; Klar E; Hopt UT; Drewelow B
    J Antimicrob Chemother; 2006 Nov; 58(5):994-9. PubMed ID: 16956903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
    Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC
    J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients.
    Esposito S; Noviello S; D'Errico G; Motta G; Passali D; Aimoni C; Pilucchi S; Fallani S; Cassetta MI; Mazzei T; Novelli A
    J Antimicrob Chemother; 2006 Apr; 57(4):789-92. PubMed ID: 16504997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetration of moxifloxacin into liver tissue.
    Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
    Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.
    Mason JW; Florian JA; Garnett CE; Moon TE; Selness DS; Spaulding RR
    J Clin Pharmacol; 2010 Nov; 50(11):1249-59. PubMed ID: 20145260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absolute bioavailability of moxifloxacin.
    Ballow C; Lettieri J; Agarwal V; Liu P; Stass H; Sullivan JT
    Clin Ther; 1999 Mar; 21(3):513-22. PubMed ID: 10321420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery.
    Metallidis S; Charokopos N; Nikolaidis J; Alexiadou E; Lazaraki G; Koumentaki E; Tsona A; Theodoridis G; Nikolaidis P
    Int J Antimicrob Agents; 2006 Nov; 28(5):428-32. PubMed ID: 17034992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations.
    Goudah A; Hasabelnaby S
    Chemotherapy; 2010; 56(1):26-31. PubMed ID: 20197659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study.
    Tzepi I; Vergados I; Kanellakopoulou K; Papathanassiou M; Kranidioti H; Tsaganos T; Liarakos V; Giamarellos-Bourboulis EJ; Theodossiadis P
    Int J Antimicrob Agents; 2009 Feb; 33(2):160-2. PubMed ID: 18947985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction.
    Stass H; Bührmann S; Mitchell A; Kubitza D; Möller JG; Kribben A; Wenzel RR; Schäfers RF
    Br J Clin Pharmacol; 2007 Dec; 64(6):745-9. PubMed ID: 17555469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects.
    Stass H; Nagelschmitz J; Moeller JG; Delesen H
    Int J Clin Pharmacol Ther; 2004 Jan; 42(1):23-9. PubMed ID: 14756383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of gastric bypass surgery on azithromycin oral bioavailability.
    Padwal RS; Ben-Eltriki M; Wang X; Langkaas LA; Sharma AM; Birch DW; Karmali S; Brocks DR
    J Antimicrob Chemother; 2012 Sep; 67(9):2203-6. PubMed ID: 22577100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections.
    Ober MC; Hoppe-Tichy T; Köninger J; Schunter O; Sonntag HG; Weigand MA; Encke J; Gutt C; Swoboda S
    J Antimicrob Chemother; 2009 Nov; 64(5):1091-5. PubMed ID: 19734170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux-en-Y gastric bypass bariatric subjects.
    Montanha MC; Dos Santos Magon TF; de Souza Alcantara C; Simões CF; Silva SRB; Kuroda CM; Yamada SS; de Oliveira LES; Nasser D; Junior NN; Mazucheli J; Diniz A; Paixão PJPA; Kimura E
    Br J Clin Pharmacol; 2019 Sep; 85(9):2118-2125. PubMed ID: 31215676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration.
    Cárceles CM; Serrano JM; Marín P; Escudero E; Fernández-Varón E
    J Vet Med A Physiol Pathol Clin Med; 2006 Aug; 53(6):300-4. PubMed ID: 16901274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitreal penetration of oral moxifloxacin in humans.
    Lott MN; Fuller JJ; Hancock HA; Singh J; Singh H; McGwin G; Marcus DM
    Retina; 2008 Mar; 28(3):473-6. PubMed ID: 18327141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers.
    Hart D; Weinstein MP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):375-8. PubMed ID: 17449210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.